Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 22/11/2020
SIETES contiene 93161 citas

 1 a 20 de 38 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Plessis L, Gómez A, García N, Cereza G, Figueras A. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia - a restraint to the potentiality for signal detection. Eur J Clin Pharmacol 2017;73:3 de marzo. [Ref.ID 101453]
2. Cita con resumen
Guinovart MC, Figueras A, Llop JC, Llor C. Obtaining antibiotics without prescription in Spain in 2014: even easier now than 6 years ago. . J Antimicrob Chemother 2015;70:1270-1. [Ref.ID 98714]
3.Enlace a cita original
Llop R, Bosch M, Figueras A, Laporte JR. Separating the wheat from the chaff: essential information in therapeutics. Eur J Clin Pharmacol 2012;68:abril. [Ref.ID 92598]
4. Cita con resumen
Moyano J, Figueras A. A review of opioid prescription in a teaching hospital in Colombia. Journal of Pain Research 2012;5:237-42. [Ref.ID 92115]
8. Cita con resumen
Figueras A, del Valle JM, Valdés JC. Consumption costs of inappropriate medicines estimated from bulk purchase data: the example of NSAIDs in Guatemala. Int J Clin Pharmacol Ther 2006;44:566-71. [Ref.ID 78493]
Castel JM, Figueras A, Vigo JM. The internet as a tool in clinical pharmacology. Br J Clin Pharmacol 2006;61:787-90. [Ref.ID 77144]
10. Cita con resumen
Montané E, Durán M, Capellà D, Figueras A. Scientific drug information in newspapers: sensationalism and low quality. The example of therapeutic use of cannabinoids. Eur J Clin Pharmacol 2005;61:475-7. [Ref.ID 74858]
11. Cita con resumen
Napchan B-M, Pinheiro Morales M, Carvalho ML, Cunha KV, Figueras A. From suspicion to action: the chemical conjunctivitis and silver nitrate connexion example in Brazilian hospitals. Pharmacoepidemiol Drug Saf 2005;14:555-9. [Ref.ID 74564]
12. Cita con resumen
Vacca C, Orozco J, Figueras A, Capellà D. Assessment of risks related to medicine dispensing by nonprofessionals in Colombia: clinical case simulations. Ann Pharmacother 2005;39:527-32. [Ref.ID 73142]
13. Cita con resumen
Mino-León D, Figueras A, Amato D, Laporte JR. Treatment of type 2 diabetes in primary health care: a drug utilization study. Ann Pharmacother 2005;39:441-5. [Ref.ID 73137]
14. Cita con resumen
Figueras A, Narváez E, Aguilera C, Laporte JR. Securing reproductive rights. Lancet 2004;363:989. [Ref.ID 69538]
15. Cita con resumen
Castel JM, Figueras A, Pedrós C, Laporte JR, Capellà D. Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Saf 2003;26:1049-55. [Ref.ID 68311]
16. Cita con resumen
Reggi V, Balocco-Mattavelli RB, Bonati M, Breton I, Figueras A, Jambert E, Kopp C, Montane E, Rägo L, Rocchi F, on behalf of the International Comparative Study On Drug Information (ICSODI) Collaborative Group. Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol 2003;59:263-70. [Ref.ID 67150]
17. Cita con resumen
Pandolfini C, Bonati M, Reggi V, Figueras A. Regulatory assessment of new drugs in developing countries. Lancet 2003;362:249-50. [Ref.ID 66919]
18. Cita con resumen
Buschiazzo H, Chaves A, Figueras A, Laporte JR. Drug utilization in Latin America - the example of DURG-LA. Essent Drugs Monit 2003;32:17-8. [Ref.ID 66877]
19. Cita con resumen
Diogène E, Pérez Peña J, Figueras A, Furones A, Debesa F, Laporte JR, on behalf of the National Pharmacoepidemiology Network. The Cuban experience in focusing pharmaceuticals policy to health population needs: initials results of the National Pharmacoepidemiology Network (1996-2001). Pharmacoepidemiol Drug Saf 2003;12:405-7. [Ref.ID 66662]
20. Cita con resumen
Figueras A, Laporte JR. Failures on the therapeutic chain as a cause of drug ineffectiveness. BMJ 2003;326:895-6. [Ref.ID 65818]
Seleccionar todas
 1 a 20 de 38 siguiente >>